[White Paper] USP 800 Gap Analysis, A Business Perspective

March 16, 2017

There are quite a few articles and great resources for developing and conducting a comprehensive Gap Analysis around the compliance details defined in the United States Pharmacopeia (USP) chapter <800>. Despite the title of this article we do not intend on simply repeating those articles, instead we want to address details for performing a gap analysis focused on the business side of the compliance equation. USP 800 is going to financially impact your pharmacy’s future business model so this article will focus on five important details that define the "why" for considering the capital investment. In this article we will offer up some examples that show how the gap analysis is a simple and effective analytical process that can help you understand if the capital investment is advantageous. It is difficult to design a "one size fits all" hazardous drug handling compliant facility without taking into consideration your pharmacy's specific business model, but towards the end of this article we will propose a financial model based on some generic assumptions to put capital investment into business perspective.

No Previous Flipbooks

Next Flipbook
[White Paper] Can a Class I and Class II BSC be in the same Sterile Hazardous Drug (HD) Room?
[White Paper] Can a Class I and Class II BSC be in the same Sterile Hazardous Drug (HD) Room?

USP 800 does not directly address the pre-sterilization process of a sterile preparation creating the quest...